Stephens Inc. AR Acquires 9,982 Shares of Zoetis Inc. $ZTS

Stephens Inc. AR boosted its holdings in Zoetis Inc. (NYSE:ZTS) by 7.7% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 139,027 shares of the company’s stock after purchasing an additional 9,982 shares during the quarter. Stephens Inc. AR’s holdings in Zoetis were worth $20,342,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently made changes to their positions in ZTS. Halbert Hargrove Global Advisors LLC boosted its stake in shares of Zoetis by 496.6% in the third quarter. Halbert Hargrove Global Advisors LLC now owns 173 shares of the company’s stock valued at $25,000 after buying an additional 144 shares during the period. REAP Financial Group LLC raised its holdings in Zoetis by 201.5% in the 2nd quarter. REAP Financial Group LLC now owns 196 shares of the company’s stock valued at $31,000 after acquiring an additional 131 shares in the last quarter. NewSquare Capital LLC raised its holdings in Zoetis by 69.1% in the 2nd quarter. NewSquare Capital LLC now owns 208 shares of the company’s stock valued at $32,000 after acquiring an additional 85 shares in the last quarter. ORG Partners LLC lifted its position in shares of Zoetis by 56.8% during the 2nd quarter. ORG Partners LLC now owns 232 shares of the company’s stock valued at $37,000 after acquiring an additional 84 shares during the period. Finally, Financial Consulate Inc. acquired a new stake in shares of Zoetis during the 3rd quarter worth $39,000. Institutional investors and hedge funds own 92.80% of the company’s stock.

Analyst Upgrades and Downgrades

ZTS has been the subject of several recent analyst reports. The Goldman Sachs Group raised shares of Zoetis to a “buy” rating in a research report on Monday, December 15th. Bank of America cut shares of Zoetis from a “buy” rating to a “neutral” rating and set a $135.00 target price for the company. in a research report on Monday, December 15th. Morgan Stanley set a $160.00 price target on shares of Zoetis in a research report on Thursday, December 18th. KeyCorp assumed coverage on shares of Zoetis in a research note on Thursday, November 20th. They issued a “sector weight” rating on the stock. Finally, Barclays began coverage on shares of Zoetis in a research report on Monday, December 8th. They set an “equal weight” rating and a $136.00 price objective for the company. Six analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $160.18.

Zoetis Stock Performance

NYSE ZTS opened at $124.60 on Wednesday. The firm’s fifty day moving average price is $122.90 and its two-hundred day moving average price is $140.04. The stock has a market cap of $54.91 billion, a PE ratio of 20.98, a PEG ratio of 2.55 and a beta of 0.97. The company has a debt-to-equity ratio of 1.31, a quick ratio of 2.28 and a current ratio of 3.64. Zoetis Inc. has a fifty-two week low of $115.25 and a fifty-two week high of $177.40.

Zoetis (NYSE:ZTS) last released its quarterly earnings data on Tuesday, November 4th. The company reported $1.70 earnings per share for the quarter, beating the consensus estimate of $1.62 by $0.08. Zoetis had a return on equity of 57.19% and a net margin of 28.21%.The company had revenue of $2.40 billion for the quarter, compared to the consensus estimate of $2.42 billion. During the same quarter last year, the business posted $1.58 EPS. Zoetis’s revenue for the quarter was up .5% on a year-over-year basis. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. On average, equities analysts expect that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Zoetis Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, March 3rd. Shareholders of record on Tuesday, January 20th will be issued a dividend of $0.53 per share. This represents a $2.12 dividend on an annualized basis and a yield of 1.7%. The ex-dividend date of this dividend is Tuesday, January 20th. This is a positive change from Zoetis’s previous quarterly dividend of $0.50. Zoetis’s payout ratio is presently 33.67%.

Zoetis Company Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.